The RegiSONIC Disease Registry Study: Treatment of vismodegib-related adverse events (AEs) in patients with locally advanced basal cell carcinoma - 09/05/15
Mario Lacouture, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Julie Guillen, University of California, San Francisco, San Francisco, CA, United States; Ragini Kudchadkar, Winship Cancer Institute of Emory University, Atlanta, GA, United States; Gary Rogers, Beverly Hospital, Beverly, MA, United States; Thomas Olencki, Ohio State University Medical Center, Columbus, OH, United States; Jean Tang, Stanford University School of Medicine, Redwood City, CA, United States; Simon Yoo, Northwestern University, Chicago, IL, United States; Susan Fish, Genentech, Inc, South San Francisco, CA, United States; Elizabeth Dawn Flick, Genentech, Inc, South San Francisco, CA, United States; Edward McKenna, Genentech, Inc, South San Francisco, CA, United States; Diana Chen, Genentech, Inc, South San Francisco, CA, United States; Yong Mun, Genentech, Inc, South San Francisco, CA, United States; Aleksandar Sekulic, Mayo Clinic, Scottsdale, AZ United States
Le texte complet de cet article est disponible en PDF.| Funded by Roche-Genentech. |
Vol 72 - N° 5S1
P. AB193 - mai 2015 Retour au numéro
Article précédent
- The prognostication of sentinel lymph node biopsies in Merkel cell carcinoma
- Topical clobetasol propionate has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I-III actinic keratoses
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?